These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6694840)

  • 1. [Long-term anticoagulant therapy in old age].
    Bán A
    Orv Hetil; 1984 Jan; 125(4):205-10. PubMed ID: 6694840
    [No Abstract]   [Full Text] [Related]  

  • 2. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin-acenocoumarol interaction.
    Mondillo S; Ballo P; Galderisi M
    Clin Ther; 2005 Jun; 27(6):782-4. PubMed ID: 16117985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?
    Barcellona D; Vannini ML; Fenu L; Balestrieri C; Marongiu F
    Thromb Haemost; 1998 Dec; 80(6):899-902. PubMed ID: 9869157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconsidering combined antiplatelet and anticoagulant therapy in atrial fibrillation.
    Falk RH
    J Am Coll Cardiol; 2004 Oct; 44(8):1567-9. PubMed ID: 15489086
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of acenocoumarol on hemorheological parameters.
    Vayá A; Martínez M; Fernández A; Ripoll F; Moscardó F; Mira Y; Aznar J
    Clin Hemorheol Microcirc; 2001; 24(2):111-5. PubMed ID: 11381186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic study of factor X during oral anticoagulation with acenocoumarol: potential value for the initiation of treatment.
    Aiach M; Fiessinger JN; Capron L; Nussas C; Housset E; Leclerc M
    Thromb Haemost; 1982 Feb; 47(1):69-71. PubMed ID: 7071808
    [No Abstract]   [Full Text] [Related]  

  • 8. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
    Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM
    Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acenocoumarol therapy in pediatric patients.
    Bonduel M; Sciuccati G; Hepner M; Torres AF; Pieroni G; Frontroth JP; Serviddio RM
    J Thromb Haemost; 2003 Aug; 1(8):1740-3. PubMed ID: 12911587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A thromboembolic predisposition and the effect of anticoagulants on migraine.
    Wammes-van der Heijden EA; Tijssen CC; van't Hoff AR; Egberts AC
    Headache; 2004 May; 44(5):399-402. PubMed ID: 15147246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prospective studies on the effectiveness of long-term anticoagulant treatment in coronary disease].
    Markiewicz M; Koziara Z; Florkiewicz H; Miturzyńska-Stryjecka H
    Pol Tyg Lek; 1981 Mar; 36(10):369-71. PubMed ID: 7024941
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.
    Pérez-Gómez F; Alegría E; Berjón J; Iriarte JA; Zumalde J; Salvador A; Mataix L;
    J Am Coll Cardiol; 2004 Oct; 44(8):1557-66. PubMed ID: 15489085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The potentiation of the anticoagulant effect of acenocoumarol by cefonicid].
    Puente García M; Bécares Martínez FJ; Merlo Arroyo J; García Sánchez G; García Díaz B; Cervero Jiménez M
    Rev Clin Esp; 1999 Sep; 199(9):620-1. PubMed ID: 10568163
    [No Abstract]   [Full Text] [Related]  

  • 14. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of prolonged acenocoumarol therapy on bone density].
    Kiss J; Tihanyi L; Nagy E; Végh Z; Deli A; Tahy A; Korányi L
    Orv Hetil; 1995 Sep; 136(39):2113-5. PubMed ID: 7566945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Don't forget the Marevan!].
    Bjerke E
    Tidsskr Nor Laegeforen; 2014 Oct; 134(19):1860. PubMed ID: 25314989
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of immunosuppressors, anticoagulants and antiphlogistic drugs on experimental Masugi nephritis. II. Acenocoumarol.
    Juska D; Tyszkiewicz Z; Gawlik Z; Lewandowska T
    Patol Pol; 1979; 30(4):505-28. PubMed ID: 542352
    [No Abstract]   [Full Text] [Related]  

  • 18. [A retrospective survey on practice of oral anticoagulant therapy in patients with cardiovascular diseases].
    Katona A; Márk L
    Orv Hetil; 2004 Aug; 145(32):1643-7. PubMed ID: 15384862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
    Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.